Background Short-video platforms increasingly shape public access to cancer information. Yet platform visibility and engagement do not necessarily reflect clinical usefulness. Objective We compared the information ecology, quality, reliability, and CRC17 completeness of default-search videos on Douyin and Bilibili in China. We also assessed whether popularity and search rank reflected information quality. Methods In this cross-sectional content analysis, we recorded the first 110 logged-out default-search results for the Chinese term colorectal cancer on each platform on 27 July 2026. Two clinical reviewers independently evaluated eligible videos using the Global Quality Scale (GQS), five-item modified DISCERN (mDISCERN), and a 17-item CRC completeness checklist. A third expert adjudicated disagreements. Analyses included non-parametric tests, agreement statistics, Wilson intervals, bootstrap Spearman correlations, multiplicity adjustment, and prespecified regression diagnostics in R 4.6.1. Results Of 220 records, 170 were included (Douyin, 109; Bilibili, 61). Median GQS (4 vs 4) and mDISCERN (3 vs 3) did not differ by platform. Bilibili had higher CRC17 completeness (6 [IQR 4–7] vs 4 [3–6]; Hodges-Lehmann difference, 1 item; rank-biserial correlation, 0.309; 95% CI, 0.124–0.473; q = .0029), particularly for etiology and symptoms. Duration was positively correlated with CRC17 completeness (rho = .396; 95% CI, .260-.522; q < .001). Neither the platform-standardized interaction index nor search rank provided a significant quality signal. Inter-rater agreement was moderate by weighted kappa and ICC, whereas Gwet AC2 for GQS was higher. Conclusions Bilibili provided more complete disease-specific information despite similar general presentation quality and reliability. Longer videos were associated with greater completeness, whereas popularity and default search rank did not provide reliable quality signals.

Abstract Background Surgery is a primary treatment modality for cancer, yet it is associated with postoperative complications, including postoperative cognitive dysfunction (POCD), which can adversely affect recovery and quality of life. Multiple non-pharmacological approaches, including electroacupuncture (EA), transcutaneous electrical acupoint stimulation (TEAS), and transcutaneous auricular vagus nerve stimulation (taVNS), are employed to mitigate POCD. However, direct comparisons of their relative efficacy are lacking. Objective This network meta-analysis aimed to comparatively assess the efficacy of distinct acupoint electrical stimulation modalities—EA, TEAS, and taVNS—in alleviating POCD among surgical oncology patients. Methods In accordance with Cochrane guidelines, a systematic review coupled with network meta-analysis was undertaken. Randomized controlled trials (RCTs) investigating acupoint electrical stimulation therapies for POCD in cancer patients were searched in databases including CNKI, Wanfang, VIP, CBM, PubMed, Embase, Web of Science, and Cochrane Library from inception to November 1, 2024. Study quality was assessed using the Cochrane Risk of Bias tool. Network meta-analysis was performed using the BUGSnet package in R 4.3.2. Outcome measures included Mini-Mental State Examination (MMSE) scores and the incidence of POCD on postoperative 1-day, 3-day, and 7-day. Results Twenty-three RCTs involving 2055 patients and 6 interventions were included, namely EA, TEAS, taVNS, sham EA, sham TEAS, and blank control. Network meta-analysis revealed that for MMSE scores on postoperative 1-day and 3-day, EA and TEAS showed statistically significant differences compared to blank controls, whereas taVNS did not. By postoperative 7-day, no significant differences were observed among EA, TEAS, taVNS, and blank controls in MMSE scores. For POCD incidence on 1-day and 3-day, EA and TEAS demonstrated significant differences compared to sham EA, sham TEAS, and blank controls. By postoperative 7-day, EA and TEAS remained significantly superior to sham TEAS and blank controls in reducing POCD incidence. Cumulative probability ranking indicated that TEAS had the highest probability of being the best for MMSE scores on 1-day and 3-day, while EA ranked highest for MMSE at 7 days, and for reducing POCD incidence at all time points. Conclusion Based on probability rankings, TEAS may be more effective in improving postoperative MMSE scores, whereas EA appears superior in reducing POCD incidence. However, due to modest differences in ranking values and methodological limitations, these findings indicate trends rather than establishing definitive superiority. Systematic review registration PROSPERO CRD42024617801.

BackgroundDespite the advancements in therapeutic regimens, gastric cancer is still among the most concerning cancer-related public health problems. In previous literature, Traditional Chinese Medicine (TCM) proved to be an effective treatment strategy for reducing the side effects of chemotherapy and improving the quality of life among patients with gastric cancer or precancerous gastric lesions.ObjectivesTo analyze the efficacy of TCM combined with chemotherapy in individuals with gastric cancer and precancerous gastric lesions.MethodsPubMed, Cochrane Library, and Embase electronic databases were utilized to perform predefined search criteria for the identification and selection of studies based on eligibility criteria. The assessed outcomes include complete response rates (CRR), disease control rate (DCR), symptom scores, and quality of life (QoL), while the secondary outcomes include immune function, tumor markers, clinical symptom scores, and gastrointestinal adverse events. Random effect models were used to perform statistical tests (SMD: standardized mean difference, OR: odds ratio) with 95% confidence intervals and heterogeneity through I2 statistics. Publication bias was evaluated using funnel plots and tests like Egger’s regression or Begg’s correlation.ResultsA total five studies reporting diverse outcomes were included in this meta-analysis. The SMD analysis for primary outcomes reported 0.35 [-0.66; 1.35] with considerable heterogeneity (I2 = 89.7%) while the CRR indicated remarkable improvement for combined therapy with OR of 4.20 [1.20; 14.71] and no heterogeneity. SMD analysis for QoL outcomes was also considerably high at 0.82 [-0.07; 1.81] with I2 = 80.0%. TCM combination group showed a significant difference in event rate with OR of 0.42 [0.32; 0.54], while the detailed analysis for symptom score of pooled -0.35 SMD [-0.76; 0.77] was obtained for fatigue, pain, acid reflux, nausea &vomiting, diarrhea. The publication bias assessment revealed significant asymmetry.ConclusionThe incorporation of TCM combined with chemotherapy for gastric cancer proved to be a safe and more effective treatment as the drug side effects were completely eradicated. The combination therapy has shown overall effectiveness with primary and secondary patient-reported outcomes, improving quality of life in gastric cancer individuals.

The purpose of this study was to conduct a systematic review and meta-analysis to investigate the association between the utilization of metformin and the occurrence and survival rate of esophageal cancer (EC) in individuals with diabetes. Methods: A systematic review and a meta-analysis were performed. Related literature was searched from databases, including PubMed, Embase, Web of Science, and Cochrane Library, covering the period from the inception of these databases until July 2023. Results: A total of 16 studies were eligible, including twelve reporting incidences of EC and four reporting OS of EC patients. The combined findings revealed a significant association between the use of metformin and a lower risk of EC (OR, 0.87, P = 0.04). Furthermore, metformin could significantly prolong the OS time (HR, 0.87, P = 0.002). In analyses stratified by treatment modalities, metformin combined with surgery and neoadjuvant chemoradiotherapy presented the strongest protective effect on EC patients with diabetes (HR, 0.38, P = 0.003). Conclusion: Our meta-analysis indicated that the use of metformin might reduce the EC incidence and improve the OS in EC patients with diabetes.

Backgrounds:Cervical cancer ranks among the most common malignant tumors affecting women globally. Currently, radiotherapy and chemotherapy are commonly used treatments for cervical cancer, yet they are often accompanied by severe toxic side effects. Therefore, enhancing the efficacy of radiotherapy and chemotherapy while mitigating their adverse reactions has become a critical challenge in contemporary cervical cancer treatment. Exploring or developing novel combination therapy regimens has also emerged as a significant research direction. Astragalus Polysaccharides, a natural extract derived from the traditional Chinese medicinal herb Astragalus membranaceus (Huang Qi), is currently widely used in China as an adjunctive therapy for various cancers. Objective:This systematic review aims to determine the clinical efficacy and safety of Astragalus Polysaccharide Injection (APS) combined with chemoradiotherapy for cervical cancer based on existing data. Methods:Systematic searches were conducted in PubMed, Web of Science, Embase, Cochrane Library, China National Knowledge Infrastructure (CNKI), Wanfang Data, Chinese Scientific Journal Database (VIP), SinoMed, and China Clinical Trials Registry Platform. The search period spanned from the inception of each database to August 1, 2025. The ROB2 tool was used to evaluate the quality of included RCTs. Meta-analysis was performed using Review Manager software, and sensitivity analysis was conducted with Stata 18 software. Evidence quality was assessed using the GRADE system. Additionally, TSA was employed to calculate the final required sample size for this meta-analysis and to validate the reliability of conclusions. The protocol for this systematic review was registered and published in PROSPERO (CRD420251139830). Results:This study included 9 RCTs involving 776 patients. Meta-analysis results showed that compared with chemoradiotherapy alone, APS combined with chemoradiotherapy improved the objective response rate (ORR, RR = 1.43, 95% CI: 1.24-1.64) and disease control rate (DCR, RR = 1.16, 95% CI: 1.08-1.24), and Karnofsky Performance Status (KPS) score (MD = 6.64, 95% CI: 4.12-9.16). It also modulates immune function: CD3+ T lymphocyte ratio (MD = 14.51, 95% CI: 1.64-27.39), CD4+ T lymphocyte ratio (MD = 4.87, 95% CI: 1.79-7.96), and CD4+/CD8+ ratio (MD = 0.25, 95% CI: 0.17-0.33). Furthermore, APS combined with chemoradiotherapy further reduced tumor marker levels, including: CEA (MD = -1.24, 95% CI: -1.58 to -0.89), SCC (MD = -1.18, 95% CI: -1.51 to -0.84), and CA125 (MD = -9.12, 95% CI: -18.22 to -0.01). Subgroup analyses of ORR and DCR suggest that APS can enhance the clinical efficacy of radiotherapy and chemotherapy for cervical cancer, respectively. TSA indicated that the results for ORR, DCR, and ADRs were certain, with other trials unlikely to alter the findings. Conclusion:APS combined with chemoradiotherapy improves response rates, enhances immune function, and reduces treatment-related toxicity in cervical cancer; however, confirmation through larger, high-quality multicenter RCTs is warranted. Systematic Review Registration:https://www.crd.york.ac.uk/PROSPERO/recorddashboard, identifier CRD420251139830.

BackgroundEarly detection of esophageal cancer (EC) is an effective strategy for reducing mortality. This study aims to construct a predictive nomogram based on a questionnaire survey to assess the risk of EC in the Chinese population and achieve risk stratification.MethodsTo ensure and verify the performance of the nomogram, we have established partnerships with 45 research institutions in 10 provinces in China. Our study comprised a total of 4016 participants (3423 participants were considered for the development and internal validation of the nomogram, while 593 participants were considered for the independent external validation). Data were collected via standardized questionnaires, and relevant predictors were screened using a least absolute shrinkage and selection operator (LASSO) and multivariate logistic regression analysis. Finally, 10 core predictive factors were selected based on clinical significance and predictive performance to construct the predictive nomogram. The performance of the nomogram was evaluated using the area under the receiver operating characteristic curve (AUC) and calibration curves, while its clinical benefit was assessed using decision curve analysis (DCA) and clinical impact curves (CIC).ResultsIn the training cohort, using LASSO regression technology, multivariate logistic regression analysis, and consideration of the clinical significance of variables, 10 predictive factors were ultimately selected to construct a nomogram, including nutritional status, preference for hot food, rate of eating, fruit intake, preference for pickled food, preference for hard food, sex, vegetable intake, age, and cooking oil intake. The nomogram performed well in both the internal validation (corrected AUC = 0.806) and external validation datasets (corrected AUC = 0.843). The calibration curve showed that the nomogram was in good agreement with the observed outcomes. The results of DCA and CIC show that our nomogram demonstrated favorable clinical consistency.ConclusionThis study developed a nomogram, which has been proven to be a convenient, economical, and accurate tool for effectively predicting the risk of developing EC in individual Chinese populations, enabling risk stratification, and serving as a pre-screening tool prior to endoscopic screening for EC.

Background and aim:While oral Chinese herbal medicine (OCHM) is frequently used for cancer pain (CP), its combined effects with opioids remain unclear. This study aims to evaluate the efficacy and safety of OCHM combined with opioids in patients with moderate to severe CP. Experimental procedure:We systematically searched five Chinese and English databases up to December 30th, 2024, for randomized controlled trials comparing OCHM plus opioids versus opioids alone. Primary outcomes were pain relief and pain intensity. Secondary outcomes included onset and duration of pain relief, Karnofsky Performance Status (KPS) score, and adverse events. Results:Meta-analysis of 18 trials revealed that OCHM plus opioids had a lower pain intensity (standardized mean difference [SMD] = -1.70; 95 % CI = -2.31 to -1.08; P < 0.001), higher incidence of pain relief (risk ratio [RR] = 1.25; 95 % CI = 1.20 to 1.31; P < 0.001) and KPS score (mean difference [MD] = 11.32; 95 % CI = 7.17 to 15.47; P < 0.001), shorter onset time of pain relief (MD = -13.27 minutes; 95 % CI = -14.42 to -12.11; P < 0.001), longer duration of pain relief (MD = 2.67 hours; 95 % CI = 2.13 to 3.21; P < 0.001), lower incidence of nausea/vomiting (RR = 0.51; 95 % CI = 0.41 to 0.62; P < 0.001), and constipation (RR = 0.60; 95 % CI = 0.51 to 0.69; P < 0.001). Conclusion:OCHM plus opioids improved pain relief, enhanced the quality of life, reduced opioid-related adverse events in patients with moderate to severe CP compared to opioids alone.

Background The use of antidepressants has increased over the years, but the relationship between antidepressant use and the risk of breast cancer is not uniform because of confounding factors. We aimed to assess the effect of antidepressants on breast cancer risk using a two-sample Mendelian randomization (MR) approach.stet Methods Secondary data analysis was performed on pooled data from genome-wide association studies based on single-nucleotide polymorphisms that were highly correlated with antidepressants, SSRI drugs, and serotonin and prolactin levels were selected as instrumental variables to evaluate the association between antidepressants and SSRI drugs and prolactin levels with breast cancer and ER+/ER- breast cancer. We then performed a test of the hypothesis that SSRI drugs elevate prolactin concentrations. We performed two-sample Mendelian randomization analyses using inverse variance weighting, MR-Egger regression, and weighted median methods, respectively. Results There was no significant risk association between antidepressant and SSRI use and the development of breast cancer, ER-positive or ER-negative breast cancer ( P > 0.05), and serotonin concentration was not associated with breast cancer risk ( P > 0.05). There was a positive causal relationship between prolactin levels and breast cancer (IVW, P = 0.02, OR = 1.058) and ER-positive breast cancer (Weighted median, P = 0.043, OR = 1.141; IVW, P = 0.009, OR = 1.125). Results in SSRI medication and prolactin levels showed no association between SSRI analogs and prolactin levels ( P > 0.05). Conclusion Large MR analysis showed that antidepressants as well as SSRI drugs were not associated with breast cancer risk and the SSRI-prolactin-breast cancer hypothesis did not hold in our analysis.

BackgroundComplementary and alternative medicine (CAM) has emerged to combat the global COVID-19 pandemic. However, no studies have been conducted to evaluate the attitudes, knowledge, and barriers of Chinese clinical and nursing students in implementing CAM during this period.ObjectiveThe aim of this study was to investigate the attitude, knowledge, and barriers of Chinese clinical and nursing students in using CAM in the context of COVID-19.MethodsAn online-based cross-sectional survey was carried out among Chinese medical students, majoring in clinical medicine or nursing, in Nanjing, Jiangsu Province, and Zhengzhou, Henan Province from May to July, 2022. A total of 402 clinical and 644 nursing students responded to a self-administered questionnaire through the Questionnaire Star and WeChat APPs. SPSS 25 (version 25) was used for data analysis. Proportions were compared by Chi-square test. Level of significance between groups was analyzed using independent student t-test and Mann-Whitney U test.ResultsThe average score of attitude was 46.63 (SD: 7.38) in clinical students and 49.84 (SD: 6.76) in nursing students. The top four most commonly used CAM treatments in China were proprietary Chinese medicine, diet therapy, decoction, and acupuncture and moxibustion (59.66%, 22.28%, 11.66%, 9.85%). The students had a good mastery of knowledge about CAM-based prevention and control of COVID-19 (mean score 7.36). The score of CAM knowledge in nursing students was significantly higher than that in clinical students (7.56 VS 7.04, P=0.000). Gender, grade, previous use, age, and knowledge score could affect students’ attitude towards CAM. The main barriers in spreading CAM use included time-consumption, bad taste, and fear of treatment-related pain (24.5%). Compared with clinical students, nursing students were more likely to recommend CAM to patients in the future (P=0.002).ConclusionsDuring the COVID-19 pandemic, nursing students were more positive towards CAM use, had a better mastery of CAM knowledge than clinical students. CAM is expected to provide better outcomes in COVID-19 patients. Future studies should focus on the changes in students’ attitudes over time and exploration of influencing factors on CAM use.

Objective: Observational studies showed that Type 2 diabetes increased the risk of breast cancer, and vice versa. However, it is uncertain whether the link is causal or just due to confounding factors. Using bidirectional Mendelian randomization analysis, we assessed the bidirectional causal relationship from a genetic level. Methods: Large genome-wide association studies yielded summary-level data for Type 2 diabetes and breast cancer. Results: Genetically predicted Type 2 diabetes presented no statistically significant association with overall breast cancer or its subtypes. Similarly, genetically predicted overall breast cancer or its subtypes had no causal effect on Type 2 diabetes. Sensitivity analyses yielded similar results. Conclusion: Our bidirectional Mendelian randomization studies revealed no causal links between Type 2 diabetes and breast cancer.

Background. Several abstract studies have demonstrated that metformin may be beneficial for preventing and treating endometrial cancer (EC), while the results have been inconsistent and inconclusive. This systematic review and meta -analysis aimed to investigate the association between metformin use and the incidence and mortality of endometrial cancer in diabetic patients. Methods. A systematic literature search was performed in Pubmed, EMBASE, Web of Science, Cochrane Library, SinoMed, CNKI, Wanfang Data, and VIP from inception to November 2022. The outcome measures were hazard ratios (HRs) comparing the EC incidence and mortality in patients with type 2 diabetes mellitus (T2DM) on metformin and non-metformin. A random or fixed -effects model was applied for data analysis, and subgroup analysis was performed to look for factors of heterogeneity. The Grading of Recommendations Assessment, Development, and Evaluation (GRADE) assessed the evidence's certainty. Results. Eleven studies reported data on EC incidence. The pooled results suggested that the use of metformin was associated with a significantly higher incidence of EC (HR = 1.17, 95% CI 1.09-1.26, P < 0.0001). Further, seventeen studies were included for survival analysis. The pooled data showed that metformin could significantly decrease all -cause mortality (HR = 0.62, 95% CI 0.52-0.74, P < 0.00001) and endometrial cancer -specific mortality (HR = 0.95, 95% CI 0.90, 1.00, P = 0.03). Finally, we noted that metformin was associated with significantly improving the progression -free survival (PFS) of EC patients with T2DM (HR = 0.55, 95% CI 0.44, 0.68, P < 0.00001). Conclusions. This meta -analysis did not prove that metformin was beneficial for preventing EC. However, metformin could reduce their mortality risk and prolong the progression -free survival time of EC patients with T2DM. (c) 2024 The Authors. Published by Elsevier Inc.

目的:基于郑玉玲教授治疗甲状腺癌的门诊病例资料,采用数据挖掘方法,探析并总结其用药组方规律.方法:通过肿瘤临床诊疗与患者管理一体化平台软件导出就诊于郑玉玲教授门诊的患者资料,对其病历信息、中药处方进行频数统计、聚类分析、因子分析、关联规则分析等,挖掘其中的用药规律和组方特点.结果:符合纳入条件的患者61例,纳入处方168首,高频方剂为当归芍药散、软坚消积汤、逍遥散、越鞠丸和薯蓣丸,将高频药物进行数据分析后,得到3类药物组合、11组常用药对.核心药物以性温为主,平为次,味辛为主、苦为次;归脾经居多,肺经、肝经次之;药物种类以补虚药为主,清热药及活血化瘀药次之,各占12.55％、9.04％、6.20％.结论:郑玉玲教授认为甲状腺癌与气滞、痰凝和血瘀有关,治疗以行气活血,化痰散结,补益气血为主.

Cannabis use is increasing annually but the relationship between cannabis use and cancer incidence is not uniform because of confounding factors. We aimed to assess the effect of cannabis use on cancer risk using a two-sample Mendelian randomization (MR) approach. Secondary data analyses were performed on pooled data based on Genome-Wide Association Study (GWAS), selecting data from the ICC and UK-Biobank and 23andMeInc lifetime cannabis use and cannabis use disorder related to the substance use disorders working group from the Psychiatric Genomics Consortium, then selecting highly correlated SNPs as instrumental variables. The substance use disorders working group, iPSYCH, and deCODE GWAS data, and then highly correlated SNPs were selected as instrumental variables for two-sample Mendelian randomization analyses using inverse variance weighting, MR-Egger regression, and weighted median, respectively, to evaluate the relationship between lifetime cannabis use and nine tumors, and subsequently analyzed these results in the same way using cannabis use disorders. The risk of all cancers except breast cancer was not associated with lifetime cannabis use. Our inverse variance weighting method found that lifetime marijuana use reduced the breast cancer risk (P = 0.016, odds ratio [OR] = 0.981), and we subsequently conducted analyses of cannabis use disorders and cancer risk, which showed that cannabis use disorders elevated the risk of breast cancer (P = 0.007, OR = 1.007) as well as the risk of lung cancer (P = 0.014, OR = 1.122). Large MR analyses suggest that lifetime cannabis use may reduce breast cancer risk, but cannabis use disorder exacerbates the risk of breast and lung cancer. The mechanisms responsible for this outcome remain to be investigated.

骨肉瘤是临床上最常见的骨组织恶性肿瘤,恶性程度很高,主要发病于儿童、青少年以及50岁以上的中老年人.其早期临床症状为疼痛,随着病情的发展会出现局部的肿块.骨肉瘤患者早期即可出现远处转移,极大部分患者会复发;转移或复发性骨肉瘤患者的五年生存率极低.郑玉玲教授认为癌毒内盛的微环境是导致骨肉瘤转移复发的重要原因.治疗上应着眼于整体,通过调节机体的微环境降低疾病复发率,预防骨肉瘤患者术后转移复发、减轻患者疼痛肿胀临床症状、保护骨质,改善患者的临床症状,取得了满意的疗效.临床用药以仙方活命饮为基础方,辨证施治,获得了较好的疗效.文章结合案例介绍郑教授治疗骨肉瘤经验,以期为临床提供参考.

"寒痰内阻"是食管癌发病的重要病机,临证时理应先开表闭、散寒邪,再以温阳化饮法治之,遵循中医学"先表后里"的治法,恢复人体气机升降出入,人体才能气血自化,邪逐病安.若寒邪盘踞人体半表半里之间,正气欲祛邪外出之时,应以"调和为主",逐渐恢复人体自我修复功能;若病已经完全入里,加之手术、放化疗等对人体正气的戕伐,致阳气大损,此时应扶养人体阳气,患者便多了一分生机.故在食管癌的整个治疗过程中,要始终顾护人体正气,恢复人本有的生命力,且所有的治疗方式都应在人体能耐受的情况下进行,做到"先留人,再治病".

In Traditional Chinese Medicine (TCM), tongue diagnosis is essential for symptom differentiation and treatment selection. Compared with traditional tongue diagnostic instruments, deploying a tongue diagnosis system on mobile devices is more convenient to monitor general health and facilitates the development of telemedicine. However, limited by both the quality and quantity of tongue images taken by mobile devices, extracting tongue features of the images maintains a great challenge. In this paper, we present a tongue feature extraction method on mobile devices, containing a high-accuracy tongue segmentation method based on Moment Invariants with Data Augmentation (DAMI) and an efficient and lightweight feature classification model with an attention mechanism. Meanwhile, we construct a novel tongue image dataset from mobile devices for extracting tongue features, significantly, first including sublingual images which are beneficial to extracting sublingual vein features. Extensive experiments on two datasets demonstrate the effectiveness and robustness of our method. Furthermore, our method greatly reduces the computing and storage demands compared with other current methods, providing a good prerequisite for deployment on mobile devices. Finally, to demonstrate the potential application of our proposed method, we develop a TCM intelligence tongue diagnosis application, which can be accessed through the WeChat Mini Program or web version, exhibiting its great potential in clinical diagnosis and health monitoring.

This article analyzed the etiology, current treatment and clinical status of cancer releted fatigue（CRF）from the perspective of modern medicine and traditional Chinese medicine. The incidence of CRF is high, and fatigue is its core symptom, but the pathogenesis is still unclear. Modern medical treatment methods are divided into drug therapy and non-drug therapy, and drug therapy is divided into causative therapy and symptomatic therapy. Non-drug therapy includes health education, psychological intervention, nutrition management, sleep management, exercise therapy, etc., but the effects of both are not satisfactory. In traditional medicine, it is classified into the category of ‘virtual exhaustion’. There are many clinical treatment methods and various means, single case, significant long-term efficacy, non-toxic side effects, and has been widely concerned. In this paper, the research progress and shortcomings of Chinese and Western medicine in recent years are discussed.

Professor ZHENG Yu-ling believes that patients with advanced esophageal cancer are deficiency in healthy qi and extremely excessive in pathogenic qi. The deficiency of liver,spleen,stomach,and kidney,in particular the spleen and kidney yang deficiency,causes stubborn phlegm and blood stasis accumulating in the sophagus,and then results into the cancer. Spleen and kidney yang deficiency,and stubborn phlegm and blood stasis contribute to the core pathogenesis of advanced esophageal cancer,and deficiency,phlegm and blood stasis are the primary pathogenic factors. By following the principles of warming and tonifying spleen and kidney,eliminating phlegm and removing blood stasis, Professor ZHENG Yu-ling established the Fu Gui Guanshitong Formula for the treatment of advanced esophageal cancer, and satisfactory efficacy has been achieved. In this article, the experience of Professor ZHENG Yu-ling in treating advanced esophageal cancer was summarized,and a proven case was presented.

目的 运用数据挖掘技术探讨郑玉玲中医治疗原发性肝癌的用药规律,为临床治疗肝癌提供借鉴.方法 收集、整理郑玉玲中医治疗原发性肝癌的门诊病例,建立肝癌病案数据库,对数据进行频数统计及药物关联规则、因子和聚类分析.结果 纳入病案148例、479诊次,涉及233味中药(累计频次8599次),统计分析得到柴胡、鸡内金、甘草等30个高频中药,所有中药性味、归经及功效分类统计分析:四气以温、寒、平为主,五味以甘、苦、辛为主,归经以脾、肝、胃经为主,功效分类以补虚药、消食药、活血化瘀药为主;对高频中药进行相关性分析:关联规则分析得到7个核心药组,因子分析提取出8个公因子,聚类分析得到3类药物组方.结论 郑玉玲中医治疗肝癌以补虚扶正为主,从肝、脾、胃入手,疏肝健脾,消食和胃;注重活血散结,同时辨证配伍理气、化痰、祛湿、解毒等祛邪之药,寓攻于补,攻补兼施,以达到人体与肿瘤"和谐"共存的状态.